Table 1.

Clinical characteristics of LUAD patients in training and validation cohorts

Characteristics		TCGA-LUAD (Training set)		GSE30219 (Validation set 1)		GSE31210 (Validation set 2)
		Number of cases	Percent %	Number of cases	Percent %	Number of cases	Percent %
Total		459		83		225
Age	> 60	314	68.4	46	55.4	118	52.4
	≤ 60	145	31.6	37	44.6	107	47.6
Gender	Male	214	46.6	65	78.3	104	46.2
	Female	245	53.4	18	21.7	121	53.8
Pathological Stage	Stage I	249	54.2			167	74.2
	Stage II	111	24.2			58	25.8
	Stage III	78	17			0	0
	Stage IV	21	4.6			0	0
Tstage	T1	158	34.4	69	83.1
	T2	243	52.9	12	14.5
	T3	41	9	2	2.4
	T4	17	3.7	0	0
Nstage	N0	302	65.8	80	96.4
	N1	88	19.2	3	3.6
	N2	67	14.6	0	0
	N3	2	0.4	0	0
Mstage	M0			83	100
	M1			0	0
EGFR mutation	Mutation					126	56
	Wild-type					99	44
KRAS mutation	Mutation					20	8.9
	Wild-type					205	91.1